Genentech, a wholly owned member of Roche Holding AG (SIX: RO, ROP; OTCQX: RHHBY), reported on October 10, 2026, that its investigational anti-interleukin-6 antibody vamikibart maintained improvements in vision and retinal swelling through 52 weeks in the Phase III MEERKAT and SANDCAT trials involving adults with uveitic macular edema. The findings, presented at the American Academy of Ophthalmology annual meeting in New Orleans, arrive as the United States Food and Drug Administration has accepted a Biologics License Application for the treatment, with a regulatory decision expected by July 2027. Although the longer-term data strengthen the treatment’s durability profile, one of the two pivotal studies failed to meet its prespecified primary endpoint, leaving an important statistical distinction within the regulatory evidence package.
The latest findings extend the clinical picture beyond the initial 16-week results presented in October 2025, when vamikibart demonstrated substantial improvements in visual acuity and macular thickness but produced different statistical outcomes across the two trials. Genentech now reports that approximately two-thirds of eligible participants required no further treatment after the initial 16-week period, while most of those who needed retreatment received only one additional injection. This suggests that the treatment may offer sustained control of retinal inflammation without requiring continuous monthly administration, although the company has not disclosed all the numerical details needed to establish how consistently that durability applies across doses and patient groups.
Uveitic macular edema is a potentially sight-threatening complication of uveitis, an inflammatory eye disorder that can cause fluid accumulation in the macula, the retinal region responsible for detailed central vision. Existing therapies can be effective, but corticosteroid exposure creates particular difficulties in patients susceptible to elevated intraocular pressure, glaucoma and cataract formation. Vamikibart is being developed as a locally administered, targeted non-steroid alternative, making the balance between sustained visual improvement, treatment frequency and long-term ocular safety central to its clinical and commercial prospects.
What do the 52-week MEERKAT and SANDCAT results reveal about vamikibart’s treatment durability?
The MEERKAT and SANDCAT programmes comprised two similarly designed, global, multicentre, randomised, double-masked, sham-controlled Phase III studies involving 245 and 256 participants, respectively. Patients received intravitreal vamikibart at doses of 0.25 mg or 1 mg, or a sham procedure, during an initial treatment period extending to week 16. Treatment then continued on an as-needed basis through week 52, allowing investigators to evaluate whether the initial response could be maintained without scheduled monthly injections throughout the full year.
The primary endpoint was assessed at week 16 and measured the proportion of patients gaining at least 15 letters from baseline in best-corrected visual acuity, a standardised measure of vision used in ophthalmology studies. Secondary measures included average changes in visual acuity and central subfield thickness, the latter reflecting changes in retinal swelling. The one-year follow-up therefore provides additional information about the persistence of treatment effects and subsequent injection requirements rather than replacing the original prespecified primary endpoint analysis.
According to the October 2026 update, participants receiving vamikibart continued to demonstrate improvements in visual acuity and reductions in macular thickness through week 52. Roche also reported that roughly two-thirds of eligible patients did not require retreatment after week 16, while the majority of patients who did undergo retreatment needed only one additional injection. This is potentially relevant for patients with recurrent inflammatory disease because fewer injections could reduce the frequency of treatment-related visits and procedures.
The interpretation nevertheless depends on details beyond the headline retreatment figure. The proportion relates specifically to eligible patients rather than necessarily representing every randomised participant, and the public announcement does not provide a comprehensive breakdown of retreatment frequency by dose, baseline disease activity or previous treatment exposure. It also does not provide detailed week-52 treatment differences, confidence intervals and formal statistical testing results for every endpoint. Those additional analyses will be important in determining whether the observed durability is consistent across the broader population or concentrated among patients with more responsive disease.
Why does the missed SANDCAT primary endpoint still matter despite positive one-year findings?
The clearest limitation in the vamikibart development programme emerged from the initial 16-week pivotal results, when MEERKAT met its primary endpoint but SANDCAT did not. In MEERKAT, the 1 mg dose produced an adjusted 36.9 percentage-point advantage over sham in the proportion of patients achieving at least a 15-letter improvement in visual acuity, with a reported P value below 0.0001. The 0.25 mg dose also achieved statistical significance, producing a 19.9 percentage-point treatment difference with a P value of 0.0008.
SANDCAT produced a different pattern. Its 1 mg group recorded an adjusted treatment difference of 10.9 percentage points against sham, with a P value of 0.0699, failing the prespecified statistical threshold. The 0.25 mg group showed a larger numerical difference of 20.7 percentage points, with a nominal P value of 0.0019, but the study’s predefined statistical testing hierarchy prevented this comparison from supporting a formal claim of statistical significance after the higher-dose primary comparison failed.
This distinction has direct implications for how regulators interpret the two studies. The fact that the lower dose produced a larger numerical treatment difference in SANDCAT, while the higher dose showed the stronger result in MEERKAT, introduces variability into the dose-response pattern. Although both studies generated evidence of treatment activity, the results do not support describing the entire pivotal programme as having met every prespecified primary efficacy objective.
Genentech previously suggested that variability in visual acuity measurements, differences in baseline patient characteristics and concomitant medications may have contributed to the divergent outcomes. Those explanations are plausible considerations for a heterogeneous inflammatory eye condition, but they do not independently establish why SANDCAT missed its primary endpoint. The FDA will ultimately need to evaluate whether the collective evidence, including visual acuity, anatomical outcomes, sensitivity analyses and longer-term observations, provides sufficient support for the proposed treatment indication.
Importantly, the new 52-week findings cannot retrospectively change the statistical outcome of the week-16 primary analysis. They can, however, contribute additional supportive evidence about consistency of clinical response and durability over time. The regulatory question is therefore not simply whether vamikibart demonstrated biological activity, but whether the complete programme establishes a sufficiently reliable treatment effect despite the differing pivotal results.
How meaningful are the improvements in visual acuity and retinal thickness for patients with uveitic macular edema?
The earlier pivotal data provide useful context for understanding the durability findings. In MEERKAT, patients receiving 1 mg vamikibart gained an adjusted average of 12.8 visual-acuity letters at week 16, compared with 3.5 letters in the sham group. The 0.25 mg group gained 9.6 letters, indicating that both investigated doses produced improvements beyond those observed in the comparator arm.
SANDCAT also showed numerical improvements in visual acuity, although the pattern differed from MEERKAT. Patients receiving 0.25 mg gained an average of 11.9 letters, while those receiving 1 mg gained 9.2 letters, compared with 5.0 letters among patients assigned to sham. These differences supported evidence of treatment activity, but the unsuccessful primary testing sequence meant that the secondary findings in SANDCAT could not be presented as formally significant within the prespecified testing framework.
The anatomical results reinforced the visual findings. In MEERKAT, mean central subfield thickness declined by 187.5 micrometres in the 0.25 mg group and 196.1 micrometres in the 1 mg group at week 16, compared with a 58.5-micrometre reduction with sham. SANDCAT similarly recorded reductions exceeding 190 micrometres in both vamikibart groups, compared with 43.5 micrometres among sham-treated participants.
These measurements are clinically relevant because retinal swelling can interfere with the function of the macula and contribute to impaired central vision. However, anatomical improvement and functional vision are not interchangeable outcomes, and the magnitude of retinal thinning does not necessarily predict equivalent improvement in everyday visual performance for every patient. The simultaneous assessment of visual acuity and retinal thickness therefore provides a more informative picture than either measure alone.
For patients with chronic inflammatory eye disease, sustained improvement may also have implications beyond the initial correction of retinal swelling. Repeated disease activity can create uncertainty around visual stability, treatment schedules and the ability to perform activities requiring detailed vision. Nevertheless, the public Phase III results do not establish that vamikibart prevents blindness, eliminates long-term recurrence or permanently preserves vision after treatment is discontinued.
Could vamikibart provide a clinically useful alternative to steroid-based treatments?
The established treatment landscape for uveitic macular edema includes local and systemic corticosteroids, as well as immunomodulatory medicines used in selected patients to control underlying inflammatory disease. Corticosteroids remain important because they can reduce retinal swelling and improve vision, but repeated or prolonged exposure can contribute to elevated intraocular pressure and cataract development. These complications create a clinical need for additional treatment mechanisms, particularly among patients who have experienced steroid-related adverse effects or require repeated control of inflammation.
There are already approved steroid treatments relevant to this disease. Bausch + Lomb’s Xipere, a suprachoroidal formulation of triamcinolone acetonide, is specifically indicated in the United States for macular edema associated with uveitis. The dexamethasone implant Ozurdex is also approved for non-infectious uveitis affecting the posterior segment of the eye, meaning vamikibart would enter an established therapeutic field rather than an untreated category.
Vamikibart’s proposed differentiation comes from its mechanism of action. The investigational monoclonal antibody targets interleukin-6, an inflammatory signalling protein implicated in uveitic macular edema, and has been engineered for intravitreal administration. This approach is intended to deliver targeted treatment to the eye without relying on the corticosteroid mechanism that underpins many existing local therapies.
The strategy has a scientific rationale, but the absence of corticosteroids does not automatically establish a superior safety profile. Direct comparisons would be needed to determine whether vamikibart offers better visual outcomes, fewer pressure-related complications or a meaningfully lower cumulative treatment burden than established steroid options. Its eventual clinical position may depend on the balance of these attributes rather than on its non-steroid classification alone.
Earlier evidence from the Phase I DOVETAIL study supported further investigation of vamikibart in patients with uveitic macular edema associated with non-infectious uveitis. That early study helped establish a preliminary clinical and biological rationale, while MEERKAT and SANDCAT were designed to provide more rigorous randomised evidence. The progression from early clinical activity to pivotal testing is meaningful, but approval and subsequent use will depend on the full efficacy and safety profile.
What does the one-year safety update establish about ocular inflammation and injection-related risks?
Genentech reported that vamikibart continued to demonstrate a low incidence of treatment-related ocular adverse events and intraocular inflammation during the one-year observation period. The company described the longer-term tolerability findings as consistent with the earlier safety profile, although the October 2026 announcement did not provide a complete numerical breakdown of adverse events by treatment group through week 52. This limits the extent to which the public update alone can support detailed comparisons of longer-term safety between doses.
At the earlier 16-week analysis, treatment-related ocular adverse events were reported in 4.1% and 1.3% of patients receiving the 0.25 mg and 1 mg doses, respectively, in MEERKAT. Corresponding proportions in SANDCAT were 4.7% and 3.5%. The reported incidence of intraocular inflammation was also relatively low, and no retinal occlusive vasculitis events were identified in the initial pivotal disclosures.
However, conjunctival haemorrhage and increased intraocular pressure were among the more frequently reported adverse events in the trials. These findings warrant attention because elevated pressure is already a relevant concern in the treatment of inflammatory eye disease, regardless of whether the underlying medicine contains a corticosteroid. Intravitreal administration also involves procedural risks that must be considered separately from adverse reactions attributable to the drug itself.
The inclusion of patients with previous intraocular pressure elevation or glaucoma is relevant to the applicability of the findings in clinical practice. Nevertheless, the available data do not establish that vamikibart prevents these conditions or is appropriate for every patient with a history of ocular pressure complications. A complete regulatory safety assessment will need to consider cumulative exposure, serious adverse events, treatment discontinuations and the consequences of repeat injections in addition to the initial adverse-event frequencies.
How will the FDA assess vamikibart before the expected July 2027 decision?
The United States Food and Drug Administration’s acceptance of the Biologics License Application represents an important transition from clinical development towards regulatory review. Genentech has submitted the evidence generated by MEERKAT and SANDCAT in support of vamikibart for uveitic macular edema, and the company expects a decision by July 2027. Filing acceptance confirms that the application has entered the review process, but it does not establish that the regulator has reached a favourable conclusion on efficacy, safety or the proposed prescribing information.
The review will be particularly consequential because of the differing primary endpoint outcomes. Regulators may examine the prespecified statistical hierarchy, the consistency of treatment effects across doses and studies, baseline disease characteristics and the influence of permitted concomitant treatments. The 52-week results provide information on durability and retreatment, but their regulatory contribution will depend on how those findings fit within the complete evidence package.
Vamikibart has also received orphan drug designation in the United States and European Union. The designation reflects recognition of its development for a rare condition under the applicable regulatory frameworks, but it is distinct from marketing approval and does not independently establish clinical efficacy. Regulatory applications have additionally been filed and accepted in the European Union, China and Japan, creating several potential decision points beyond the United States.
The precise approved population, dose and treatment schedule remain undetermined. Although the pivotal studies investigated adults with uveitic macular edema associated with non-infectious uveitis, the final permitted indication and prescribing conditions will depend on regulatory assessment. Any approved dosing regimen could also influence the extent to which the favourable retreatment pattern observed during the trials translates into routine clinical use.
Why does vamikibart matter commercially for Roche’s ophthalmology business?
Vamikibart represents a potential expansion of Roche’s ophthalmology portfolio into a specialised inflammatory retinal indication. The company’s existing retinal franchise includes Vabysmo, which generated CHF 2.06 billion in global sales during the first half of 2026 across its approved eye-disease indications. Vamikibart addresses a different clinical population, and its development should not be interpreted as an extension of Vabysmo’s current authorisations.
The established ophthalmology infrastructure of Genentech and Roche could provide a commercial advantage if vamikibart secures regulatory approval. Experience working with retinal specialists, intravitreal therapies and specialty distribution may reduce some operational barriers associated with introducing another injectable eye treatment. Nevertheless, uveitic macular edema is a comparatively specialised market, and treatment adoption will depend on patient identification, prescribing preferences, reimbursement, pricing and demonstrated differentiation from available therapies.
The retreatment results could become a commercially relevant characteristic if subsequent evidence supports a consistently low injection burden under routine treatment conditions. Fewer injections might reduce certain procedural and scheduling demands, but the trial results do not yet establish overall cost savings or superior resource utilisation compared with existing treatments. Payers and providers will also need to consider drug acquisition costs, administration expenses and the possibility of additional treatment for patients with persistent or recurrent disease.
From an investor perspective, vamikibart is more appropriately viewed as a pipeline and regulatory development than as an established revenue contributor. Roche participation certificates closed at CHF 357.80 on the SIX Swiss Exchange on October 9, 2026, rising approximately 1.45% during that session. Because the one-year announcement was issued on October 10, the preceding trading session cannot be interpreted as the market’s reaction to the newly disclosed data.
For Roche, the significance extends beyond the immediate scale of the uveitic macular edema market. An approval would add another targeted ophthalmology mechanism to its portfolio while potentially expanding treatment choices within a difficult inflammatory indication. The commercial outcome, however, cannot be inferred from its existing retinal franchise or from the size of the broader ophthalmology market.
What evidence will determine whether vamikibart becomes an established treatment for uveitic macular edema?
The next stage of the programme will be defined by regulatory assessment and the availability of more complete longer-term clinical data. Detailed reporting of 52-week visual acuity outcomes, retinal thickness changes, injection frequencies and adverse events would allow a clearer evaluation of whether the benefits were maintained consistently across treatment groups. Dose-specific durability findings would be particularly useful given the different response patterns observed during the original pivotal analyses.
Peer-reviewed publication of the complete Phase III evidence would also help clinicians assess the treatment’s relevance to patients with different levels of inflammatory activity, previous therapy exposure and ocular comorbidities. MEERKAT and SANDCAT enrolled a population reflecting several important features of uveitic macular edema, but real-world patients may require ongoing treatment for the underlying inflammatory disease as well as management of retinal swelling. Understanding how vamikibart fits within that broader treatment strategy will be important for clinical adoption.
The October 2026 findings provide additional evidence that vamikibart’s initial improvements in visual acuity and macular anatomy can persist through one year, with many eligible participants avoiding additional injections after the initial treatment period. They also leave intact the principal statistical limitation from the pivotal programme, namely the unsuccessful primary endpoint in SANDCAT. The FDA’s expected July 2027 decision will therefore be a test of whether the combined efficacy, durability and safety evidence is sufficiently compelling to support a new targeted non-steroid treatment for uveitic macular edema.
